Under this agreement, TNO will develop novel methods for the manufacture, formulation and testing of viral gene delivery systems such as the SVac platform of Amarna. The collaboration is partly supported by a co-financing initiative aimed at developing innovative technologies.
Ben van Leent, CEO of Amarna Therapeutics, said: We are very pleased to work with TNO. We have developed a revolutionary novel viral gene delivery vector platform technology SVac for producing human therapeutics that have the potential to save lives and improve the quality of life for millions of people worldwide that are suffering from life-threatening or severe chronic diseases.
The technology is now available to address the major diseases of our time including genetic disorders, autoimmune diseases, allergies and cancer. Amarna Therapeutics acts at the forefront of the therapeutic vaccination and gene therapy markets. Both markets are rapidly growing to reach an estimated €40 billion in 2015. I’m convinced that the therapeutics in our pipeline all have blockbuster potential. The partnership with TNO enables us to initiate the first time in man clinical trials with one of our lead therapeutics in 2010.
Menzo Havenga, managing director of Biosciences at TNO, said: The partnership between TNO and Amarna allows us to expand our pre-clinical development services into the extremely important therapeutic area of viral vector and gene delivery technologies and is yet another important step in our establishment of a fully integrated and highly innovative package of biopharmaceutical development capabilities.